BioSig recently announced that it has partnered with Charles Austin and JK partners to start scaling up its operations to prepare for the commercial launch of its Pure EP system.
Pure EP is meant to improve the quality of clinical information coming out of electrophysiology studies and cardiac catheter ablation.
Austin has over 25 years of experience in medical devices, pharmaceuticals and consumer products and recently served as the corporate VP of global supply chain at Johnson & Johnson. He was also a member of the J&J Management Committee where he was responsible for over 60,000 associates across 130 global locations while also overseeing over 500 external manufacturers, over $22B in direct spending and supported over $70B in sales. In addition to serving on various boards in the medical and consumer spaces, Austin is a principal at JK Advisors.
“BioSig has impressed us with a strong value proposition and support of leading centers of excellence in the industry. I’m delighted to join the BioSig team at this important time and contribute my knowledge to take the company to the next level,” Austin said.
“BioSig is excited to be working with an executive leader like Chuck. His 25 plus years of experience working for one of the world’s leading healthcare organizations can significantly benefit our effort to launch and expand our business operations,” said Kenneth Londoner, chairman and CEO of BioSig Technologies. “While we expect Chuck to make his initial impact on manufacturing, logistics, and operations, his experience in successfully deploying new commercial models and driving global growth in the medical device marketplace will create value for all our stakeholders. This is an excellent way to kick off our efforts in 2018, which promises to be a pivotal year for the company.”
